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RESULTS: Of 290 abstracts screened, 65 met selection criteria
and were reviewed in detail. The average direct medical costs
associated with chemotherapy-induced AEs ranged from
$8,400–$13,500 for neutropenia hospitalization, $5,300–
$7,500 per thrombocytopenia episode, and $14,500–>$114,000
annually for anemia. Key cost drivers for each AE were: neu-
tropenia—hospital length of stay, antibiotics, growth factors,
and diagnostic tests; thrombocytopenia—platelet transfusions
and major bleeding episodes; anemia—EPO-type drugs and
transfusions. Neutropenia and anemia events in patients with
hematologic malignancies resulted in direct medical costs more
than double compared to solid tumors. Indirect costs were >50%
of the direct costs. CONCLUSIONS: Hematologic AEs from
cancer treatments result in substantial economic burden for
payers, patients, and society. This burden appears particularly
heavy for the hematologic malignancies where chemotherapy-
induced hematologic AEs represent >20% of the overall cost of
treatment. Targeted therapies for hematologic malignancy offer
superior outcomes to chemotherapy with reduced AEs. However,
the hematologic toxicities of these targeted agents vary and may
affect the total cost of treatment of the underlying disease. There-
fore, in addition to treatment outcomes, AEs and the cost of
treating AEs should be taken into consideration when determin-
ing the optimal treatment for patients.
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In Romanian haemophiliacs, because of limited access to 
clotting factor concentrates, surgical interventions are made
especially in case of severe, life-threatening complications.
OBJECTIVE: To realize an economic analysis of orthopedic and
surgical interventions. METHODS: In a seven-year period, 37
haemophiliacs (from 224 haemophilia patients registered and
treated in Haemophilia Centre Timisoara) underwent 54 surgi-
cal and orthopedic interventions. We evaluated: direct medical
costs (therapy and hospitalization costs) of these interventions,
direct non-medical costs (home-hospital travel costs), indirect
costs (morbidity costs; loss of income of family members who
forfeit paid employment for haemophiliac home care; average
number of days off at school or work), treatment compliance.
Data were obtained from patients’ medical charts and from 
questionnaires administered to patients. RESULTS: Therapy
costs represented 91.14% of direct medical costs (85.8% 
in haemophilia A without high-titer inhibitors, 95.34% in
haemophilia A with high-titer inhibitors and 92.52% in
haemophilia B patients). Direct non-medical costs represented
high percents of mean patient and family income. Mean monthly
morbidity cost was €97.5 and loss of income of family members
who forfeid employment in order to offer home care for
haemophilia patients was €115.04/month. Average number of
days off at school/work was 72.59/year. CONCLUSIONS: Insuf-
ﬁcient resources lead to severe complications in haemophiliacs,
which can be life-threatening, requiring costly surgical interven-
tions. In the absence of home therapy programs and of Com-
prehensive Haemophilia Care Centers, patients have to travel
long home-hospital distances to a hospital where they can receive
treatment, delaying substitution administration, which is also
responsible for complications appearance. Poor social integra-
tion of patients has a negative impact on personal income, affect-
ing treatment compliance. It is therefore necessary a better
resource allocation for haemophilia treatment, in order to
increase direct medical costs and also to offer a better social pro-
tection of the patients.
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OBJECTIVES: For estimating the cost-effectiveness of interven-
tions to avert blood-transfusions it is important to estimate the
costs of one unit of allogeneic blood. An example of such an
intervention is administration of erythropoietin. Objective of this
study was estimating the costs per unit of erythrocytes in The
Netherlands from a societal perspective. METHODS: For the
estimation of the costs we followed the path from donor to
patient. In this path 6 steps were elaborated: donation, produc-
tion, transport, storage and preparation, administration and the
consequences of administration. In these different steps the cost-
consequences were estimated. RESULTS: Although not all cost-
factors could yet be identiﬁed, the cost-estimate is €240, for a
unit of erythrocytes. The indirect costs are responsible for
approximately 3% of the unit costs. The production and trans-
port part by the Dutch blood banks is responsible for the major-
ity of the costs. CONCLUSIONS: Internationally cost-estimates
vary widely. Cost-estimates for the United States, UK, Sweden
and Canada vary from approximately €130 to €930. For The
Netherlands we estimated the unit costs for a unit of erythro-
cytes at €240 from a societal perspective.
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OBJECTIVE: Patients with β-Thalassemia Major (TM) require
life-long blood transfusions and, to avoid iron overload, Iron
Chelation Treatment (ICT), based on 8–12 hour infusions of
Deferoxamine (DFO) for 5–7 days/week, and/or Deferiprone
(L1) orally administered. ICT regimen often causes low satisfac-
tion and low compliance, with potentially negative consequences
on patients’ health, wellbeing and costs. Aims: to investigate
direct costs of treatment in TM patients. Costs were estimated
from the societal perspective, using tariffs or prices applied in
2006. METHODS: The Italian-THAlassemia-Cost-&-Out-
comes-Assessment (ITHACA) was a naturalistic multicentre
study conducted to evaluate costs, quality of life, compliance and
treatment satisfaction in TM patients undergoing ICT. Patients
of any age, on ICT for at least 3 years, were sequentially enrolled
at 8 Italian Thalassemia Care Centers. Data on direct costs are
referred to a retrospective median observational period of 11.7
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months. RESULTS: 137 patients were enrolled (median age =
28.3 years, from 2.7 to 48.5 years, 49.6% male). At enrolment
112 (81.7%) patients had at least one thalassemia related com-
plication (42.3% had hepatic, 58.4% endocrine, 18.2% cardiac
diseases, 55.5% viral infections). Patients treated with DFO were
51.5%, 31.6% were treated with L1, 16.9% with DFO + L1.
Treatment in patients taking DFO cost on average
€552.88/patient/month plus €211.20 for pump and consum-
ables; patients taking L1 cost €383.25/patient/month, patients
taking DFO + L1 cost €918.41. Overall, mean direct cost was
€1245.33/patient/month, with ICT representing 55.4% of costs,
followed by transfusions (33.1%), hospitalizations and surgery
(3.3%), laboratory and instrumental tests and medical visits
(3.1%), concomitant medications (1.6%), non-medical costs
(transportation, 3.4%). CONCLUSION: Transfusion and ICT
account for 90% of total costs, corresponding to approximately
€1000/patient/month. These results can be considered conserva-
tive because some sources of costs (e.g. nursing, home care) were
not estimated, anyway we do not expect the amount of not
included costs would signiﬁcantly affect our results.
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People with hematological disorders such as beta thallasemia
major (TM) who regularly receive blood transfusions need iron
chelation therapy (ICT) to prevent iron overload. The drugs most
frequently given are deferoxamine and deferiprone. So far, little
is known about the costs related to iron chelation treatment.
OBJECTIVE: To receive information about indirect costs due to
ICT. METHODS: The Italian-THAlassemia-Cost-&-Outcomes-
Assessment (ITHACA) is a naturalistic, multicenter, retrospec-
tive study involving patients with TM of any age, on ICT for at
least 3 years, sequentially enrolled at 8 Italian Thalassemia Care
Centers. Indirect costs were estimated with modiﬁed versions of
the “Health and Labour Questionnaire” (HLQ). RESULTS: A
total of 116 Italian TM patients completed the HLQ. Sixty-one
patients (52.7%) were in paid employment. 21 (34.4%) had
experienced absenteeism from work due to ill health in the pre-
vious 2 weeks. The average absenteeism among patients in paid
employment was 0.7 days/week. Indirect costs related to absen-
teeism are 27.55 euros per patient a week (based on net earn-
ings). Fifteen patients (26.4% of patients in paid employment)
were hindered by health problems at work. Indirect costs per
patient based on hours needed to catch up on tasks neglected
due to health problems were 9.5 euros/week. Patients in our
study received 1.24 hours of household help/week, adding up to
64.74 hours per patient a year. No differences were detected in
the above between patients using deferoxamine, deferiprone or
a combination of both, possibly due to the limited sample size.
21 children (or their caregivers) completed the “HLQ children-
part” (average age 10.7). In the previous twelve weeks 18 chil-
dren missed schooldays (mean = 0.64 days/week) and 6 children
missed regular activities. CONCLUSIONS: TM and current
treatment strategies have a high impact on patients’ productiv-
ity leading to considerable costs. Children with TM miss school-
days on a regular basis.
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OBJECTIVE: To assess by a modeling example under which con-
ditions a combination of adult population genetic screening 
programs is cost-effective. METHODS: Based on a systematic lit-
erature review, hereditary haemochromatosis (HFE) was selected
as a potentially cost-effective primary DNA screening target. 
A secondary condition where population screening exhibits
favourable effectiveness yet unfavourable cost-effectiveness is
hereditary nonpolyposis colorectal cancer (HNPCC). A decision
tree for DNA screening for selected mutations in adult male Cau-
casians was constructed from a health care sector perspective for
HFE, HNPCC, both combined and all three alternatives includ-
ing ﬁrst-degree relatives. Cost data from a recent HFE screening
cost study in Germany were applied; HNPCC mutation preva-
lences were estimated based on data from the German HNPCC
consortium. RESULTS: The model renders a cost-effectiveness
ratio of approximately 100.000 Euro per life-year gained for the
dominated HNPCC screening option, 300 EUR/LYG for HFE
screening and 600 EUR/LYG for combined screening. Cost-effec-
tiveness is most sensitive to different values for HFE penetrance
and cost of genetic counselling found in the literature. Despite
high incremental cost-effectiveness ratios for single HNPCC
mutations added, the average cost-effectiveness ratio of the DNA
test remains moderate if high test speciﬁcity is assured. Effec-
tiveness and cost-effectiveness improve substancially if ﬁrst-
degree relatives are included. CONCLUSIONS: Rather than
disease predisposition screening for frequent single nucleotid
polymorphisms (SNPs) with low penetrance, it appears worth-
wile to screen for rare mutations with high penetrance, combined
with screening for HFE. Product developers in the in-vitro diag-
nostics industry may follow this approach to design cost-effec-
tive screening tools like DNA chips. The screening algorithm
should be designed in a way to minimize the number of false-
posities. Pre-test counselling should identify cases of familial
cancer and ensure that negative test results are not misinterpreted
as private mutations cannot be identiﬁed by a test for known
HNPCC mutations.
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OBJECTIVES: Patients with β-Thalassemia Major (MT) require
life-long blood transfusions, which often cause iron overload
that may increase patients’ morbidity and mortality. Iron 
Chelation Treatment (ICT), based on 8–12 hour infusions of
Deferoxamine for 5–7 days/week, and/or Deferiprone orally
administered, is aimed to reduce iron overload but can be related
to low satisfaction, low compliance and potentially negative con-
sequences on clinical effectiveness and patients’ wellbeing Aims:
to investigate on Health-Related Quality-of-Life (HRQoL) of
MT patients under ICT. METHODS: The Italian-THAlassemia-
Cosy-&-Outcomes-Assessment (ITHACA) was a naturalistic
multicentre study conducted to evaluate costs, HRQoL, compli-
ance and treatment satisfaction in MT patients undergoing ICT.
